{"id":3796,"date":"2026-10-20T09:00:00","date_gmt":"2026-10-20T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3796"},"modified":"2026-10-20T21:02:48","modified_gmt":"2026-10-21T01:02:48","slug":"rap-219-clears-phase-2-with-a-modest-tolerable-mania-signal","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3796","title":{"rendered":"RAP-219 Clears Phase 2 With a Modest, Tolerable Mania Signal"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Rapport Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Phase 2 Topline Results<\/p>\n

Modality<\/strong><\/p>\n

Small molecule; TARP\u03b38-selective AMPA receptor negative allosteric modulator<\/p>\n

Asset<\/strong><\/p>\n

RAP-219<\/p>\n

Target<\/strong><\/p>\n

AMPA receptors associated with TARP\u03b38<\/p>\n

Disease Area<\/strong><\/p>\n

Acute bipolar mania (bipolar I disorder)<\/p>\n

Summary<\/h4>\n

Rapport Therapeutics reported that RAP-219 met the primary endpoint in a 253-patient randomized Phase 2 trial in acute bipolar mania. The TARP\u03b38-selective AMPA receptor negative allosteric modulator produced a 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale after three weeks (p=0.045), while overall treatment-emergent adverse-event incidence was similar to placebo.<\/p>\n

The readout is a meaningful first clinical test of circuit-selective AMPA modulation, but it is not yet a decisive efficacy result. The endpoint narrowly crossed nominal significance, the placebo group improved substantially, treatment lasted only three weeks, and the eight-week safety extension is incomplete. The signal supports Phase 3 planning; it does not establish clinical differentiation from established antimanic therapy.<\/p>\n

Adults hospitalized for acute mania were randomized to RAP-219 or placebo in a double-blind US study. After titration, the active arm received 0.75 mg once daily. Baseline mean YMRS scores were 36.9 for RAP-219 and 35.8 for placebo. At week three, mean reductions were 15.4 and 12.3 points, respectively, yielding the 3.1-point placebo-adjusted difference. The key clinician-rated secondary measure, CGI-BP mania severity, improved by 0.4 points versus placebo (p=0.024).<\/p>\n

All 11 YMRS items numerically favored RAP-219; four reached nominal significance. Treatment-emergent adverse events occurred in 51.6% of the active arm and 52.8% of placebo. No severe or serious adverse events were reported during the three-week period. Discontinuations due to adverse events were 3.2% versus 0.8%. Agitation was more frequent with RAP-219 (16.7% versus 9.4%), as was nausea (5.6% versus 1.6%).<\/p>\n

Rapport plans to discuss a registrational path with FDA in the first quarter of 2027 and expects two Phase 3 trials to begin in the second half of 2027. The company reported $436.1 million in cash, cash equivalents and investments, with runway guidance into the second half of 2029.<\/p>\n

Deep Analysis<\/h4>\n

RAP-219 is designed to inhibit AMPA receptors associated with TARP\u03b38, an auxiliary protein enriched in the hippocampus and neocortex and relatively absent from hindbrain regions. The translational hypothesis is that anatomical selectivity can preserve antimanic efficacy while avoiding the broad sedation, motor impairment and cognitive burden associated with less selective suppression of excitatory neurotransmission. A tolerability profile similar to placebo is therefore central\u2014not incidental\u2014to the platform thesis.<\/p>\n

The favorable interpretation is that the trial achieved pharmacologic proof of concept in a severe inpatient population with a mechanistically differentiated agent. Concordance between the primary endpoint, the global mania scale and item-level directionality reduces the probability that the result is purely statistical noise. The absence of serious events and the lack of a broad sedation signal support the intended neuroanatomical selectivity, subject to full data disclosure.<\/p>\n

The counterinterpretation is equally important. A 3.1-point placebo-adjusted YMRS difference is modest and the p-value of 0.045 is vulnerable to small analytic or missing-data changes. Hospitalization, intensive observation and background care can drive large placebo responses. The short study does not answer whether efficacy persists, whether activation or agitation becomes limiting, or how the agent compares with lithium, valproate or atypical antipsychotics in speed, magnitude and relapse prevention.<\/p>\n

Phase 3 design will determine whether the signal compounds or collapses. Replication should pre-specify handling of rescue medications, background therapy, mixed features and site effects; include a clinically interpretable responder analysis; and characterize cognition, sleep, akathisia-like symptoms and suicidality. A successful program could create a non-dopaminergic option for acute mania. Failure to reproduce the small treatment delta would instead place the readout among statistically positive but clinically fragile neuropsychiatry studies.<\/p>\n

Company and Product Background<\/h4>\n

Rapport Therapeutics develops small molecules directed at receptor-associated proteins that define regional and cellular receptor pharmacology. RAP-219 is an oral negative allosteric modulator of AMPA receptors associated with TARP\u03b38. By exploiting the distribution of the auxiliary protein rather than targeting AMPA receptors indiscriminately, the program aims to confine activity to forebrain circuits implicated in disease.<\/p>\n

Bipolar I disorder is characterized by recurrent manic and depressive episodes. Acute mania can require hospitalization and rapid pharmacologic control. Current options are effective for many patients but can impose metabolic, motor, cognitive and sedation burdens, leaving room for mechanistically distinct agents if they deliver a clear efficacy\u2013tolerability balance.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified fact:<\/strong> randomized Phase 2 study enrolled 253 adults with acute bipolar mania and met the prespecified primary YMRS endpoint.<\/li>\n
  • Verified fact:<\/strong> placebo-adjusted benefit was 3.1 YMRS points at week three, with p=0.045.<\/li>\n
  • Company claim:<\/strong> TARP\u03b38 selectivity may deliver efficacy without off-target hindbrain effects associated with broader AMPA inhibition.<\/li>\n
  • Missing evidence:<\/strong> full statistical analysis plan, multiplicity handling, responder\/remission data, concomitant medication detail, exposure-response and completed eight-week safety follow-up.<\/li>\n
  • Interpretation A:<\/strong> circuit-selective AMPA modulation has genuine antimanic activity and a tolerability advantage worth advancing.<\/li>\n
  • Interpretation B:<\/strong> a high placebo response and narrow p-value produced an unstable effect unlikely to survive larger, more heterogeneous Phase 3 trials.<\/li>\n
  • Upgrade trigger:<\/strong> replicated Phase 3 efficacy with a larger, clinically meaningful separation and consistent responder outcomes without sedation or activation liability.<\/li>\n
  • Downgrade or falsifier:<\/strong> non-replication, worsening agitation, discontinuation imbalance, or absence of functional benefit despite score changes.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The result earns advancement but not exuberance. Rapport has shown that its receptor-associated-protein strategy can generate a measurable clinical signal in a difficult indication while maintaining encouraging short-term tolerability. The platform’s competitive value now depends on whether anatomical selectivity yields a reproducible therapeutic-index advantage, not simply a statistically positive score.<\/p>\n

    Signal direction is mixed\u2013positive: the trial de-risks mechanism and safety enough to justify registrational work, yet the effect size and statistical margin make replication risk the dominant question. Phase 3 should be designed to convert a nominal score advantage into an outcome clinicians recognize as materially different.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5 \u2014 first substantive clinical validation of a circuit-selective AMPA strategy in a severe neuropsychiatric indication. Signal Direction: Mixed\u2013positive \u2014 endpoint success and short-term tolerability are offset by modest effect size and narrow statistical clearance. Confidence in Facts: High \u2014 randomized topline results and numerical safety data are directly reported by the sponsor. Confidence in Interpretation: Moderate \u2014 full data, longer follow-up and independent replication are unavailable. Red-team conclusion: neither the title nor the take calls the drug clinically differentiated; both frame the result as a Phase 3-enabling signal.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Rapport Therapeutics reported that RAP-219 met the primary endpoint in a 253-patient randomized Phase 2 trial in acute bipolar mania. The TARP\u03b38-selective AMPA receptor negative allosteric modulator produced a 3.1-point placebo-adjusted improvement on the…<\/p>\n","protected":false},"author":1,"featured_media":3800,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1118,825,1119,1117,1116],"class_list":["post-3796","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-ampa-receptor","tag-bipolar-disorder","tag-mania","tag-rap-219","tag-rapport-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3796"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3796\/revisions"}],"predecessor-version":[{"id":3806,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3796\/revisions\/3806"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3800"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}